基于ROS介导NLRP3炎症小体活化探讨凉血退紫方治疗过敏性紫癜大鼠作用机制研究
作者:
作者单位:

河南中医药大学第一附属医院儿科医学院/河南中医药大学儿科医学院

基金项目:

]河南省省级科技研发计划联合(222301420022);国家自然科学基金(823745);2021年度河南省中原英才计划(育才系列)(豫组通[2021]44号);2023年度河南省中医学“双一流”创建科学研究专项(HSRP-DFCTCM-2023-8-41);河南中医药大学2023年度研究生科研创新类项目(2023KYCX005)


Study on mechanism of Liangxue Tuizi Formula in the treatment of Henoch-Sch?nlein purpura rats through ROS-mediated activation of NLRP3 inflammasome
Author:
Affiliation:

College of Pediatrics,The First Afiliated Hospital of Henan University of Chinese Medicine,Henan Zhengzhou

  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • | |
  • 文章评论
    摘要:

    目的 研究凉血退紫方(LXTZF)对过敏性紫癜大鼠活性氧(Reactive oxygen species, ROS)介导的NOD样受体热蛋白结构域相关蛋白3(Nod-like receptor protein 3,NLRP3)炎症小体活化的影响,探讨凉血退紫方治疗过敏性紫癜的可能作用机制。方法 将24只大鼠随机分为4组即空白组、模型组、LXTZF组、复方甘草酸苷(Compound Glycyrrhizin, CG)组,除空白组外,其余各组采用热性药物联合卵白蛋白(OVA)建立过敏性紫癜大鼠模型。造模成功后,LXTZF组予LXTZF溶液7.47 g·kg-1,CG组予CG溶液13.5 mg·kg-1灌胃,空白组和模型组给予生理盐水灌胃,1次/天,连续4周。末次灌胃8 h后取材,苏木精-伊红染色法(Hematoxylin-eosin staining, HE)观察各组大鼠皮肤组织形态学变化;酶联免疫吸附法(ELISA)检测血清白介素-18(Interleukin-18, IL-18)、白介素-1β(Interleukin-1β, IL-1β)水平;免疫荧光检测大鼠皮肤ROS水平变化;实时荧光定量PCR(Real-time quantitative PCR, RT-qPCR)法、免疫组化法及蛋白质印迹(Western Blot)法检测大鼠皮肤凋亡相关点样蛋白(Apoptosis-associated speckle-like protein, ASC)、NLRP3、半胱氨酸蛋白酶-1(Cysteinyl Aspartate-Specific Protease-1, Caspase-1)基因mRNA及蛋白表达。结果 与空白组相比,模型组大鼠皮肤组织病理可见明显炎症细胞浸润;血清IL-18、IL-1β含量均明显升高(P<0.05),皮肤ROS水平显著升高(P<0.05),皮肤ASC、NLRP3 、Caspase-1 mRNA及蛋白表达水平显著升高(P<0.05)。与LXTZF组和CG组大鼠皮肤组织病理炎症细胞浸润减轻;血清IL-18、IL-1β水平显著降低(P<0.05);皮肤ROS水平模型组比,显著降低(P<0.05),皮肤ASC、NLRP3 、Caspase-1 mRNA及蛋白表达水平显著降低(P<0.05)。结论 凉血退紫方治疗过敏性紫癜发挥作用的机制可能与抑制ROS介导的NLRP3炎症小体活化相关。

    Abstract:

    Objective To study the effect of Liangxue Tuizi Formula(LXTZF) on reactive oxygen species(ROS)-mediated NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome activation in Henoch-Sch?nlein purpura rats, and to explore the possible mechanism of Liangxue Tuizi Formula in the treatment of HSP. Methods 24 rats were randomly divided into 4 groups: blank group, model group, LXTZF group and Compound Glycyrrhizin (CG) group. Except the blank group, the rat model of a Henoch-Sch?nlein purpura was established by heat drug combined with egg albumin (OVA). After successful modeling, LXTZF group was given LXTZF solution 7.47 g·kg-1, CG group was given CG solution 13.5 mg·kg-1 by gavage, blank group and model group were given normal saline solution gavage once a day for 4 weeks. Samples were collected 8 hours after the last gavage. Hematoxylin-eosin staining (HE) was used to observe the skin histopathologic changes. Serum Interleukin-18 (IL-18) and Interleukin-1β (IL-1β) levels were detected by enzyme-linked immunosorbent assay (ELISA). The changes of ROS levels in the skin of rats were detected by immunofluorescence. Real-time quantitative PCR (RT-qPCR), immunohistochemical and western blot methods were used to detect Apoptosis-associated speckle-like protein (ASC), NLRP3, Cysteinyl Aspartate-Specific Protease-1 (Caspase-1) gene mRNA and protein expression in rat skin. Results Compared with the blank group, the skin pathology of the model group showed obvious inflammatory cell infiltration. Serum IL-18 and IL-1β levels were significantly increased (P<0.05), skin ROS levels were significantly increased (P<0.05), and skin ASC, NLRP3, Caspase-1 mRNA and protein expression levels were significantly increased (P<0.05). Compared with the model group, the infiltration of inflammatory cells in the skin tissues of rats in the LXTZF group and the CG group was alleviated, the levels of serum IL-18 and IL-1β in the CG group and LXTZF group were significantly decreased (P<0.05). The level of ROS in the skin was significantly decreased (P<0.05), and the mRNA and protein expression levels of ASC, NLRP3 and Caspase-1 in the skin were significantly decreased (P<0.05). Conclusion The mechanism of Liangxue Tuizi Formula in the treatment of Henoch-Sch?nlein purpura may be related to the inhibition of ROS-mediated NLRP3 inflammasome activation.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-10-22
  • 最后修改日期:2025-01-13
  • 录用日期:2025-03-21
防诈骗提示!请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭